This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arinaga, S. Articles by Tsuji, H. Search for Related Content PubMed PubMed Citation Articles by Arinaga, S. Articles by Tsuji, H.

Augmentation of the Generation of Cell-mediated Cytotoxicity after a Single Dose of Adriamycin in Cancer Patients

Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874, Japan

The effect of Adriamycin on the generation of cell-mediated cytotoxicity in the mixed cell culture was studied in patients with various carcinomas. Peripheral blood mononuclear cells (PBM) from the patients were cultured with the B-lymphoblastoid cell line Raji in mixed culture, and the induced cytotoxicity was measured by ⁵¹Cr release assay. In patients with various carcinomas, the capacity of PBM to be converted to cytotoxic cells was significantly augmented 5, 7, and 10 days after a single dose of 25 mg/sq m i.v., when compared to that of PBM obtained before Adriamycin injection. The peak level of the cytotoxicity observed 7 days after injection was more than 2-fold higher than that before treatment. Although the depletion of adherent cells from PBM either before or after treatment resulted in a decreased cytotoxic response, nonadherent cell fractions as well as unfractionated cells from PBM after drug treatment equally showed an augmented response when compared to that before injection. The distribution of T-cell subsets exhibited a significant increase in the percentage of OKT8 positive cells after administration. Furthermore, PBM obtained after treatment produced significantly higher levels of interleukin 2. The results appear to indicate that the imbalance of T-cell subsets and the increase of interleukin 2 production may be related to the augmenting effect of Adriamycin administration on cytotoxic response in cancer patients.

¹ To whom requests for reprints should be addressed, at Department of Surgery, Medical Institute of Bioregulation, Kyushu University 69, Beppu 874, Japan.

Received 11/12/85. Revised 4/28/86. Accepted 5/ 6/86.

This article has been cited by other articles:

				E. Mihich On The Immunomodulating Effects of Anti-Cancer Drugs and Their Therapeutic Exploitation Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 469 - 471. [Full Text] [PDF]